Drug Development Needs “Extreme Makeover,” Researcher Topol Says
Executive Summary
The pharmaceutical business needs an "extreme makeover," Cleveland Clinic cardiologist Eric Topol, MD, maintained during the 2004 Medical Innovation Summit in Cleveland
You may also be interested in...
Vioxx Withdrawal Fuels Criticism Of DTC; Liability Exposure May Be Test
The Vioxx withdrawal will prompt renewed debate over DTC advertising
COX-2 Class Is TARGET Of Critical Lancet Editorial
The TARGET study's mixed results on Novartis' Prexige prompted an editorial critique of the entire COX-2 inhibitor class of drugs
Rx Industry Pricing Model Must Change, Former Merck CEO Vagelos Says
The pharmaceutical industry needs to rethink its approach to pricing or face dire consequences, former Merck CEO Roy Vagelos told the Pharma, Biotech & Device Colloquium in Princeton, N.J. June 9